17:16 EDT AIM ImmunoTech (AIM) files $100M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech made ‘significant strides’ over course of 2024
- AIM announces principal investigator for Ampligen, FluMist clinical study
- AIM ImmunoTech Appoints David Chemerow to Board
- AIM ImmunoTech appoints Chemerow as an Independent Director
- AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi